Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

BACKGROUND: Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6. In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in combination with letrozole improved progression-free survival (PFS) compared with letrozole alone as first-line treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Finn, Richard S., Crown, John P., Ettl, Johannes, Schmidt, Marcus, Bondarenko, Igor M., Lang, Istvan, Pinter, Tamas, Boer, Katalin, Patel, Ravindranath, Randolph, Sophia, Kim, Sindy T., Huang, Xin, Schnell, Patrick, Nadanaciva, Sashi, Bartlett, Cynthia Huang, Slamon, Dennis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924326/
https://www.ncbi.nlm.nih.gov/pubmed/27349747
http://dx.doi.org/10.1186/s13058-016-0721-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924326/
https://www.ncbi.nlm.nih.gov/pubmed/27349747
http://dx.doi.org/10.1186/s13058-016-0721-5

Ejemplares similares